Cerity Partners LLC Has $39 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Cerity Partners LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 72.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,032 shares of the company’s stock after acquiring an additional 157,788 shares during the quarter. Cerity Partners LLC’s holdings in Novo Nordisk A/S were worth $39,004,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornerstone Planning Group LLC bought a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $29,000. Tower Research Capital LLC TRC increased its stake in shares of Novo Nordisk A/S by 165.3% in the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after buying an additional 124 shares in the last quarter. Pacific Center for Financial Services raised its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth about $28,000. Finally, Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after acquiring an additional 141 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 0.7 %

NYSE:NVO opened at $124.52 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The firm has a market capitalization of $558.79 billion, a P/E ratio of 46.03, a P/E/G ratio of 2.09 and a beta of 0.41. The stock’s fifty day simple moving average is $125.93 and its 200-day simple moving average is $109.61.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Equities research analysts expect that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on NVO shares. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday. They issued an “outperform” rating and a $163.00 target price for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.